What this means
Researchers plan to give a weekly drug or a placebo to teens with craniopharyngioma and obesity. This trial has not started recruiting, so it cannot yet show whether the drug works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 12–17 · Teens aged 12 to 17 with craniopharyngioma and hypothalamic obesity; no results posted yet
- Where
- 17 sites
The science
- Registered title
- SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
- Trial ID
- NCT07845994 ↗
- Phase
- PHASE 3
- Study type
- interventional
- Conditions
- Craniopharyngioma, Child
- What is tested
- Semaglutide (Wegovy) weekly injection, Placebo weekly Injection
- Sponsor
- University Hospital, Angers
- Ages
- 12 Years to 17 Years
- Dates
- First posted Sep 29, 2026 · updated Sep 29, 2026
Registry summary
Craniopharyngioma (CP) is a rare embryonic brain tumor of the sellar and parasellar region. Despite its benign histologic characteristics, it is locally aggressive and may cause severe morbidity from invasion into adjacent tissues and structures. Hypothalamic damage due to the tumor or its management is responsible for rapid and massive obesity, one of the most severe sequelae in patients with craniopharyngioma. Current treatment of craniopharyngioma is neurosurgical, possibly completed by radiotherapy. For preventing hypothalamic damage, surgery is the most "sparing" possible for the hypothalamus, possibly completed by a highly conformation radiation treatment, such as proton beam therapy.
Despite these therapeutic advances, obesity remains a significant problem in 30 to 50% of cases today. Most studies showed that the mean BMI at diagnosis of childhood craniopharyngioma was 0.5-0.8 ± 1.5 SD score, the mean BMI gain was +2 to +3 ± 2 SD score within 3 years, with a relative stabilization or a slow increase after 3 years. When there is an anterior and posterior hypothalamic involvement (about 50% of the cases), the mean BMI gain is even higher (+4 ± 3 SD score within 3 years).
Semaglutide, a GLP1RA in weekly injection, has shown its great effectiveness for losing weight in obese adults and adolescents (mean difference in BMI change - 16.7% with semaglutide vs. placebo after 68 weeks). Preliminary data in obese children with craniopharyngioma have shown a mean 25% difference in annual BMI gain (with semaglutide treatment compared to the previous year with no semaglutide in the same children).
Sites (17)
- Service Endocrinologie pédiatrique, Angers University Hospital, Angers, France
- Endocrinologie Pédiatrique, University hospital of Besançon, Besançon, France
- Service d'endocrinologie, diabétoglogie et obésité pédiatrique, Bordeaux University Hospital, Bordeaux, France
- Endocrinologie Pédiatrique, Hôpital Femme Mere Enfants, Lyon University Hospital, Bron, France
- Département de Pédiatrie, Dijon University Hospital, Dijon, France
- Service de Pédiatrie, Grenoble University Hospital, La Tronche, France
- Endocrinologie et diabète de l'enfant, Hopital Bicêtre, Paris University Hospital, Le Kremlin-Bicêtre, France
- Endocrinologie, diabète et obésité pédiatrique, Lille University Hospital, Lille, France
- Service de pédiatrie multidisciplinaire, Hopital La Timone, Marseille University Hospital, Marseille, France
- Service de diabétologie et endocrinologie pédiatriques, Montpellier, France
- Unité Endocrinologie et Diabète, Nancy University hospital, Nancy, France
- Endocrinologie, diabétologie et Gynécologie pédiatrique, Necker Hospital, Paris University Hospital, Paris, France
- Service d'endocrinologie diabétologie pédiatrique, Paris University Hospital, Paris, France
- Service de Pédiatrie A, Reims University Hospital, Reims, France
- Unité d'Endocrinologie et Diabétologie Pédiatriques, Rennes University Hospital, Rennes, France
And 2 more on the listing.